Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Salloway

Showing results (101-110 of 174) with videos related to

Pageof 18
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 30, 2018
Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's diseaseStephan Müller, Oliver Preische, Hamid R Sohrabi, et al.
Nature|June 23, 2017
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's diseaseJeff Sevigny, Ping Chiao, Thierry Bussière, et al.
Acta Neuropathologica|June 16, 2026
Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer's diseaseLindsay A Welikovitch, Derek H Oakley, Rachel E Bennett, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 8, 2026
Plasma levels of an N-terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's diseaseStephanie A Schultz, Yiwen Rao, Lei Liu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 10, 2012
Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug developmentAdam L Boxer, Michael Gold, Edward Huey, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 15, 2017
Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's diseaseBelinda M Brown, Hamid R Sohrabi, Kevin Taddei, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|August 11, 2017
Performance of [<sup>18</sup>F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's diseaseStephen Salloway, Jose E Gamez, Upinder Singh, et al.
Journal of Alzheimer'S Disease : JAD|August 29, 2016
A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer's DiseaseAndres M Lozano, Lisa Fosdick, M Mallar Chakravarty, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 6, 2024
The POINTER Imaging baseline cohort: Associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognitionTheresa M Harrison, Tyler Ward, Jacinda Taggett, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 2, 2021
Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer diseaseVirginia D Buckles, Chengjie Xiong, Randall J Bateman, et al.
Pageof 18

Showing results (101-110 of 174) with videos related to

Sort By:
Pageof 18
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 30, 2018
Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's diseaseStephan Müller, Oliver Preische, Hamid R Sohrabi, et al.
Nature|June 23, 2017
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's diseaseJeff Sevigny, Ping Chiao, Thierry Bussière, et al.
Acta Neuropathologica|June 16, 2026
Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer's diseaseLindsay A Welikovitch, Derek H Oakley, Rachel E Bennett, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 8, 2026
Plasma levels of an N-terminal tau fragment predict Alzheimer's and neurodegenerative disease biomarkers in autosomal dominant Alzheimer's diseaseStephanie A Schultz, Yiwen Rao, Lei Liu, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 10, 2012
Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug developmentAdam L Boxer, Michael Gold, Edward Huey, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 15, 2017
Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's diseaseBelinda M Brown, Hamid R Sohrabi, Kevin Taddei, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|August 11, 2017
Performance of [<sup>18</sup>F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's diseaseStephen Salloway, Jose E Gamez, Upinder Singh, et al.
Journal of Alzheimer'S Disease : JAD|August 29, 2016
A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer's DiseaseAndres M Lozano, Lisa Fosdick, M Mallar Chakravarty, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 6, 2024
The POINTER Imaging baseline cohort: Associations between multimodal neuroimaging biomarkers, cardiovascular health, and cognitionTheresa M Harrison, Tyler Ward, Jacinda Taggett, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 2, 2021
Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer diseaseVirginia D Buckles, Chengjie Xiong, Randall J Bateman, et al.
Pageof 18